In the news

Ketan Thought Leadership

Ketan Thought Leadership (ONNJ interview) in onnj.com

Maruishi Deal in BioSpectrum Asia

Evergreen Cebranopadol Coverage in Anesthesiology News

Conba Announcement in Discover Pharma

Adneuris Launch By ROI-NJ Staff (Monmouth Junction)

Rethinking Acute Pain Management: The Next Frontier of Pain Relief with James Hackworth – Episode 266 in Life Science Podcast

Opinion: New painkillers critical to fight opioid epidemic, broader pain crisis in BioSpace

Tris’ next-gen pain drug completes trio of clinical wins, setting up push to FDA in Fierce Biotech

Cebranopadol shows lower abuse potential compared to existing pain therapies in Drug Topics

Tris looks to take on opioids with latest cebranopadol data in Citeline

Tris Pharma’s alternative to opioids reduces post-surgery pain in phase 3 trial ahead of NDA submission in Fierce Biotech

Tris Pharma awarded up to $16.6M to advance treatment for opioid use disorder in New Jersey Business Magazine

First-in-class dual NMR agonist

First-in-class dual NMR agonist

2031 US Highway 130, Suite A
Monmouth Junction, NJ 08852

732-940-2800

Copyright notice © 2026 Adneuris Therapeutics. All rights reserved.
Adneuris is a wholly owned subsidiary of Tris Pharma, Inc.